Renal dysfunction increases the risk of saphenous vein graft occlusion: Results from the Post-CABG trial

Atherosclerosis

Volumn 193, Issue 2, 2007, Pages 414-420

  Wellenius, Gregory A ^a   Mukamal, Kenneth J ^a   Winkelmayer, Wolfgang C ^b   Mittleman, Murray A ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Division of Pharmacoepidemiology and Pharmacoeconomics   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Atherosclerosis; Chronic kidney disease; Coronary artery bypass graft surgery; Epidemiology; Saphenous vein graft

Indexed keywords

COLESTYRAMINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; WARFARIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT OCCLUSION; GRAFT PATENCY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SAPHENOUS VEIN GRAFT; VEIN GRAFT DISEASE;

AGED; CHRONIC DISEASE; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; RISK FACTORS; SAPHENOUS VEIN;

EID: 34447303329     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.07.008     Document Type: Article

References (32)

1. American Heart Association. Heart disease and stroke statistics-2005 update (2004), American Heart Association, Dallas, TX
2. Lytle B.W. Prolonging patency-choosing coronary bypass grafts. N Engl J Med 351 (2004) 2262-2264
3. Motwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97 (1998) 916-931
4. Campeau L., Enjalbert M., Lesperance J., et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 311 (1984) 1329-1332
5. Neitzel G.F., Barboriak J.J., Pintar K., and Qureshi I. Atherosclerosis in aortocoronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 6 (1986) 594-600
6. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-266.
7. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 (2003) 2154-2169
8. Manjunath G., Tighiouart H., Ibrahim H., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41 (2003) 47-55
9. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 (2004) 1285-1295
10. Gardner S.C., Grunwald G.K., Rumsfeld J.S., et al. Risk factors for intermediate-term survival after coronary artery bypass grafting. Ann Thorac Surg 72 (2001) 2033-2037
11. van de Wal R.M., van Brussel B.L., Voors A.A., et al. Mild preoperative renal dysfunction as a predictor of long-term clinical outcome after coronary bypass surgery. J Thorac Cardiovasc Surg 129 (2005) 330-335
12. Lemos P.A., Serruys P.W., de Feyter P., et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol 95 (2005) 445-451
13. Blacher J., London G.M., Safar M.E., and Mourad J.J. Influence of age and end-stage renal disease on the stiffness of carotid wall material in hypertension. J Hypertens 17 (1999) 237-244
14. Wang M.C., Tsai W.C., Chen J.Y., and Huang J.J. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 45 (2005) 494-501
15. Zoungas S., Ristevski S., Lightfoot P., et al. Carotid artery intima-medial thickness is increased in chronic renal failure. Clin Exp Pharmacol Physiol 27 (2000) 639-641
16. Fox C.S., Larson M.G., Keyes M.J., et al. Kidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: the Framingham Heart Study. Kidney Int 66 (2004) 2017-2021
17. Reis S.E., Olson M.B., Fried L., et al. Mild renal insufficiency is associated with angiographic coronary artery disease in women. Circulation 105 (2002) 2826-2829
18. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997; 336:153-162.
19. Modification of Diet in Renal Disease Study Group, Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
20. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
21. Campeau L., Hunninghake D.B., Knatterud G.L., et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation 99 (1999) 3241-3247
22. Shlipak M.G., Fried L.F., Crump C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107 (2003) 87-92
23. Gyongyosi M., Glogar D., Weidinger F., et al. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction. Am Heart J 147 (2004) 158-164
24. Libby P. Act local, act global: inflammation and the multiplicity of "vulnerable" coronary plaques. J Am Coll Cardiol 45 (2005) 1600-1602
25. Koenig W., Twardella D., Brenner H., and Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol (2006)
26. Ix J.H., Mercado N., Shlipak M.G., et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J 149 (2005) 512-519
27. Shlipak M.G., Fried L.F., Cushman M., et al. Serum Lp(a) level as a predictor of traditional and novel risk factors. JAMA 77 (2005) 1737-1745
28. Hoff H.F., Beck G.J., Skibinski C.I., et al. Elevations of inflammatory and procoagulant biomarkers in patients. Circulation 77 (1988) 87-92
29. Hillis G.S., Croal B.L., Buchan K.G., et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation 113 (2006) 1056-1062
30. Stevens L.A., Coresh J., Greene T., and Levey A.S. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354 (2006) 2473-2483
31. Best P.J., Berger P.B., Davis B.R., et al. Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. J Am Coll Cardiol 44 (2004) 1786-1791
32. Lemos P.A., Arampatzis C.A., Hoye A., et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol 95 (2005) 167-172